Gilles Salles, MD, PhD

Experts discuss how long-term data influence current and future approaches to first-line diffuse large B-cell lymphoma (DLBCL) treatment, exploring how these outcomes shape perspectives on DLBCL treatment evolution and highlighting the most compelling aspects of emerging data for advancing clinical practice.

Experts discuss the decision-making factors and real-world challenges that shape treatment selection in diffuse large B-cell lymphoma (DLBCL) patient care. They focus on how efficacy data, safety profiles, and patient factors influence treatment choices, and the implementation challenges encountered when introducing newer regimens into practice.

Experts discuss how disease progression impacts patients with diffuse large B-cell lymphoma (DLBCL) and strategies for managing progressive disease based on first-line therapy selection, incorporating insights from the POLARIX 5-year subsequent treatment data and highlighting quality-of-life considerations that influence treatment decisions.

Experts discuss polatuzumab’s effectiveness across germinal center B-cell (GCB) and activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL) subgroups, including updates to published data. They also explore how different molecular classification methods compare in clinical practice to guide treatment selection, with insights on differential responses across specific molecular or clinical subgroups.

Experts discuss clinical experience with established and emerging treatment approaches in diffuse large B-cell lymphoma (DLBCL), including R-CHOP and polatuzumab-based regimens, and the factors guiding treatment selection for first-line DLBCL, along with observed outcomes across different patient subgroups.

Experts discuss how the 5-year outcomes of polatuzumab have influenced its position in current NCCN guidelines for diffuse large B-cell lymphoma (DLBCL) treatment, offering insights on how to interpret and apply these recommendations in various patient scenarios.

Experts discuss the 5-year efficacy and safety outcomes of polatuzumab in diffuse large B-cell lymphoma (DLBCL), highlighting its meaningful progression-free survival (PFS) and overall survival (OS) results for first-line patients with DLBCL and emphasizing key long-term safety considerations for clinicians.

The use of bispecific antibodies has the potential to revolutionize the management of FL.

Future directions for follicular lymphoma treatments include potential use earlier in treatment or as combination therapy, identifying patients who will benefit most from treatment, and minimizing the costs of therapy while maximizing accessibility.

Closing out the program, Dr Gilles Salles highlights currently unmet needs in DLBCL and investigational treatments he finds exciting.

Dr Gilles Salles shares his opinion on the presented case’s treatment decision and the regimen he would have selected for the patient.

Gilles Salles, MD, PhD, explains data on the adverse events seen with the pola-BR regimen in R/R DLBCL during the GO29365 clinical trial.

A review of population, dosing, and efficacy data from the GO29365 clinical trial investigating the combination of polatuzumab, bendamustine, and rituximab (pola-BR) for R/R DLBCL.

Dr Salles provides an overview of the available third-line treatment options for patients with R/R DLBCL who are ineligible for or do not wish to receive autologous stem cell transplant or CAR T-cell therapy.

An oncologist describes the typical major challenges of managing patients with R/R DLBCL and the incidence of relapsed or refractory disease.

Gilles Salles, MD, PhD, presents the case of a 51-year-old woman with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.